Prime Medicine said New Zealand’s Medsafe cleared its clinical trial application for PM-577a, a Prime Editor for Wilson’s disease. The company positioned PM-577a as investigational and designed for precise genome editing, aiming to address the genetic basis of the rare disorder. The clearance is a regulatory milestone that allows Prime Medicine to progress from development activities into clinical dosing and protocol execution within New Zealand. For investors, the step reduces friction to initiating human studies and provides a defined regulatory timetable. The move also underscores the growing focus on Prime Editing platforms, which aim to perform targeted edits with different tradeoffs than older CRISPR approaches, while Prime Medicine continues to expand its clinical footprint across indications.